Needham Downgrades Artiva Biotherapeutics to Hold
Needham analyst Gil Blum downgrades Artiva Biotherapeutics (NASDAQ:ARTV) from Buy to Hold.
Share
Why It Matters
An expert investor called Needham decided Artiva is not a great buy right now. When experts change their mind like this, it is worth thinking about why.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.